Company profile
Phico Therapeutics Limited is a UK company with status active founded in 2000 based in South East England.
Updated 06 Jun 2026 16:52
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
MR04 | Transaction MzQzNTM5NDgwMWFkaXF6a2N4
Published 12 Sep 2024 10:45
Next accounts due date
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jun 2020 to 30 Nov 2020
no public description
1 Mar 2018 to 31 Dec 2021
"Phico is a biotechnology company developing a novel platform technology, SASPject, to treat infections, particularly those due to antibiotic resistant bacteria. Phico is developing an intravenous SASPject, PT3.8 targeted against Pseudomonas aeruginosa which causes 10% of all hospital infections and is a major cause of hospital acquired and ventilator ass...
1 Sep 2014 to 31 Dec 2016
Phico is developing a novel antibacterial technology called SASPject, that can be targeted to selected harmful bacteria. SASPject is not affected by antibiotic resistance mechanisms and works by disabling bacterial DNA in a way that bacteria cannot avoid. This project will enable Phico to complete the pre-clinical development of SASPject PT3 targeted to P...
1 Dec 2012 to 31 Mar 2013
Antibiotic resistance is a global healthcare crisis. There are now bacteria which are resistant to every marketed antibiotic and these are spreading around the world (HPA, 2011). The World Health Organisation’s World Health Day in 2011 “Antibiotic resistance – no action today no cure tomorrow” shows development of novel antibiotics that can treat resistan...
